SCHAUMBURG, Ill., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
About Flumazenil Injection, USP
Flumazenil injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose.
The package insert, available at www.sagentpharma.com, contains the indications, boxed warning, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605Source:Sagent Pharmaceuticals, Inc.